Betterlife Pharma Inc. · CSE:BETR
Betterlife Pharma — Investor Presentation (August 2022)
15 slides from Betterlife Pharma's investor presentation, August 2022
Slide 1: Working to build a BetterLife, with innovative medicines
Working to build a BetterLife, with innovative medicines. We aim to provide the market with widely available; extensively affordable; globally regulation free; and diversely applicable medicines. Our compound will be the go-to medicine that will be able to treat the vast array of mental health probl
Slide 2: Investment Highlights
Vision: To deliver patient-friendly mental health solutions by producing unregulated, economical, curative, and safe prescription medicines for the global market. Team: Highly Experienced Pharma Team with Significant Track Record in Developing & Commercializing Successful Therapeutics. Investment Hi
Slide 3: A Fast Growing Problem - Worldwide
Mental Disorder More and more people are suffering from mental disorders. In a forecast by Mordor Intelligence, the global antidepressants market alone is expected to grow at a CAGR of 2.68% during the forecast period of 2019-2027. Today‘s business and life culture is demanding more and more commitm
Slide 4: BETR-001 – A promising Solution
BETR-001 – A promising Solution In the last 10 years, psychedelics have again BetterLife has set out to develop a non- been intensively researched. More and more hallucinogenic medicine that will have the studies are showing the potential benefits positive effects of psychedelics but will of psyched
Slide 5: BETR-002
BETR-002 A novel formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound, with potential for treatment of benzodiazepine dependency, anxiety, and other neurological disorders. Its active pharmaceutical ingredient is dihydrohonokiol-B (“DHH-B”). DHH-B is a derivative of honokiol
Slide 6: Indications: Major Depression Disorder (MDD)
Indications Major Depression Disorder (MDD) Mental disorder characterized by a sustained feeling of sadness or loss of pleasure and or interest in life. Economic Burden worldwide to be about $1 trillion/year. Approximately 280 million people in the world have depression. (1) DEPRESSION IS A LEADING
Slide 7: Indications: Cluster Headaches (CH)
Indications Cluster Headaches (CH) Extremely intense headaches with short attacks range 15-180 minutes and can occur several times a day. Medical costs, work Over absence & productivi- 7,000,000 Sufferers 30% ty loss from CH & mig- lost or limited raines is estimated at people are affected their car
Slide 8: Indications: Neuropathic Pain (NeP)
Indications Neuropathic Pain (NeP) Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. The origin of neuropathic pain is diverse and related to a large variety of often difficult to treat underlying diseases or lesions. Symptoms include localized or widespread
Slide 9: Indications: Post Traumatic Stress Syndrom (PTSD)
Indications Post Traumatic Stress Syndrom (PTSD) Psychiatric disorder that people develop after having experienced/wit- nessed a traumatic event in their life. Global Drug Sales for PTSD Estimated to reach over US$ 1 billion. 1 in 13 people will develop PTSD at some point in their life. ABOUT 8 MILL
Slide 10: Indications: Benzodiazepine Dependency (BZD)
Indications Benzodiazepine Dependency (BZD) Class of drugs used to tranquilize symptoms of anxiety, panic disorders, insomnia, muscle tension and seizures. Usually prescribed for short- term relief over a few weeks because it is highly addictive. Benzodiazepines Market size is projec- ted to reach U
Slide 11: Program Planning
Program Planning Program Discovery Preclinical IND Phase I Phase II Phase III Major Depressive Disorder 20% BETR-001 Neuropathic pain 20% BETR-001 Cluster Headaches 20% BETR-001 PTSD 20% BETR-001 Benzodiazepine Dependency 10% BETR-002 BetterLife Pharma / 11
Slide 12: Market
Global sales of psychiatric drugs could reach more than $40bn by 2025. According to GlobalData, sales of psychiatric drugs are expected to increase from US$ 27.4 billion in 2020 to US$ 40.9bn in 2025, growing at a compound annual growth rate (CAGR) of 8.4%. Market Global annual sales forecast of dru
Slide 13: Management Team
Management Team BetterLife Pharma /
Slide 14: Management Advisors
Hooshmand Sheshbaradaran, PhD Management Chief Operating Officer Anthony Calandra, PhD 30+ years senior pharma executive drug Head Regulatory development, operations, licensing and M&A 30+ years of pharmaceutical and regulatory affairs Ahmad Abdi Ghaffari, PhD Doroudian, Head of Preclinical PhD Rese
Slide 15: Thank you. Contact
Thank you. Contact CEO: Ahmad Doroudian, Ph.D. BetterLife Pharmaceuticals Inc. 1275 West 6th Avenue, # 300 Vancouver, BC V6H 1A6 Canada Tel: +1 (0)604 221-0595 ahmad.doroudian@blifepharma.com BetterLife Pharma / 15
BetterLife Pharma — Investor Presentation (August 2022) on 6ix